Abstract: Disclosed are a polybutadiene having a controlled microstructure, a narrow molecular weight distribution, minimal gel content, and a low APHA color, a modified polybutadiene, producing methods for both, and a rubber-reinforced styrene resin composition using the same. The polybutadiene of the present invention is characterized in that the ratio (Tcp/ML1+4) of a 5% toluene melting viscosity (Tcp) measured at 25° C. and the Mooney viscosity (ML1+4) at 100° C. is 2.0 or higher, the molecular weight distribution (Mw/Mn) is 2.80 or less, the gel content is 0.06 wt % or less, and the APHA color is 20 or less.

Abstract: Organopolysiloxanes containing both acidic and basic groups are prepared by reacting oganopolysiloxanes with primary or secondary amino groups with a stoichiometric deficiency of isocyanates containing sulfonyl-group-containing electron withdrawings groups in the presence of acidic or basic moderators.

Abstract: A method for forming a high molecular weight thermotropic liquid crystalline polymer is provided. The method includes melt polymerizing two or more monomers in the presence of a unique aromatic amide oligomer to form a prepolymer, and then solid-state polymerizing the prepolymer to achieve a target molecular weight. The present inventors have discovered that a unique aromatic amide oligomer can be employed to help increase the “low shear” complex viscosity of the resulting solid-state polymerized composition. This allows for the attainment of higher than conventional “low shear” complex viscosity values and/or a substantial reduction in the solid-state polymerization time needed to achieve a target complex viscosity. In addition, the oligomeric flow aid can also accelerate the extent to which the “high shear” melt viscosity is increased during solid-state polymerization, which may also contribute to a substantial reduction in the solid-state polymerization time needed to achieve a certain molecular weight.

Abstract: The invention provides a non-painting and high-gloss polycarbonate resin composition. Specifically, the invention provides a polycarbonate resin composition having a superior impact strength, heat-resistance, electric characteristics, weather resistance, and light resistance. In certain embodiments, the resin composition of the invention is obtained by mixing a butadiene-based impact modifier, such as acrylonitrile-butadiene-styrene (ABS) or methacrylate-butadiene-styrene and an acryl-based impact modifier in polycarbonate resin, followed by adding an ultraviolet (UV) absorbent to the mixture.

Abstract: Compounds having a core comprised of an aromatic ring and at least two annulated beta-substituted fused thiophene ring systems of the general formula: -(?-R2—FT2ArFT2-?-R2)—, and polymers or copolymers thereof, of the general formulas: -{-(?-R2—FT2ArFT2-?-R2)-G1-}n-, or -{-G1-(?-R2—FT2ArFT2-?-R2)-G1-G2-}n-, where ?-R2—FT2ArFT2-?-R2, -G1-, -G2-, and n are as defined herein. Also disclosed are compositions, articles, or devices comprising the polymers, and methods for making and using the polymers. The compositions, articles, or devices can be used, for example, for electronic applications, such as light emitting devices and semiconductor devices.

Abstract: A method of removing a residual catalyst metal compound from a polymer solution comprises the steps of: a) mixing a solution in which at least one organic nitrogen compound is dissolved in a polar solvent and the polymer solution to precipitate a chelate compound of the organic nitrogen compounds and the residual catalyst metal compound, b) adding the polar solvent to the solution mixture to dissolve a chelate compound and to precipitate a polymer, and c) filtering the precipitated polymer. After the polymer polymerization is completed, an organic nitrogen compound solution is added to perform a chelate reaction with the residual catalyst metal compound in a solution phase, and the polar solvent is added to precipitate the polymer so that only polymer precipitates are filtered while an additional filtration process in respect to the chelate compound is not performed to easily remove the residual catalyst metal compound.

Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.

Abstract: A peptide for targeting bone marrow consists of about 5 to about 25 amino acids and includes an amino acid sequence that targets the peptide to bone marrow.

Abstract: The invention relates to mTORbeta, a splice form of mTOR, nucleic acids encoding mTOR beta, and antibodies against mTOR beta. The invention also relates to methods of producing mTOR beta and methods of screening for an agent that modulates mTOR beta expression and/or activity. The invention further relates to a method of treating a disease associated with aberrant expression of mTOR beta by administration of an agent that alters mTOR activity and/or expression.

Abstract: The present invention relates to a novel hypoglycemic/anti-hyperglycemic protein named ADMc1 purified from the seeds of Momordica charantia for control of hyperglycemia. The process for the purification of novel hypoglycemic/anti-hyperglycemic protein named ADMc1 is also disclosed. The invention also relates to process for preparation and purification of the recombinant novel hypoglycemic/anti-hyperglycemic protein of Momordica charantia, named rADMc1. Both ADMc1 and rADMc1 are highly effective and need to be administered only once a day to maintain normal blood glucose levels. The procedure involves purification of a novel hypoglycemic/anti-hyperglycemic protein of M. charantia, construction of cDNA library from M. charantia seeds, screening of cDNA library using oligonucleotide probe designed on the basis of amino acid sequence of the tryptic fragment of the protein, cloning of the cDNA in a eukaryotic expression system, expression and purification of the recombinant protein.

Abstract: This invention relates to chimeric and humanized antibodies that specifically bind the BCR complex, and particularly chimeric and humanized antibodies to the BCR complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.

Abstract: The embodiments of the invention relate to compositions, methods, and kits comprising a fusion protein. The fusion proteins of the embodiments include monomer polypeptides which in one embodiment have at least a binding domain, an optional hinge region, a collagen-like domain and the Fc domain of a human IgG.

Abstract: Canavan disease, an autosomal recessive leukodystrophy, is caused by deficiency of aspartoacylase and accumulation of N-acetylaspartic acid in brain. Human aspartoacylase (ASP) cDNA spanning 1,435 bp has been cloned and expressed in E. coli. A base change, a854>c, has been found in 85% of the 34 Canavan alleles tested so far, which results in a missense glu285>ala mutation that is predicted to be part of the catalytic domain of aspartoacylase. The invention therefore provides nucleic acid sequences, genes, polypeptides, antibodies, vectors containing the gene, host cells transformed with vectors containing the gene, animal models for the disease, methods for expressing the polypeptide, genetic screening methods and kits, diagnostic methods and kits, methods of treating Canavan disease and methods of genetic therapy for the disease.

Abstract: The present invention provides novel antagonistic anti-human CD40 monoclonal antibodies, methods for generating them and uses thereof.

Abstract: The present invention concerns a process for producing compositions that are rich in secretory IgA (S-IgA) by fractionating milk containing S-IgA. Such compositions may be used in particular for treating and/or preventing infections and/or inflammation of the mucosal surfaces, e.g. the gastro-intestinal tract, urogenital tract, respiratory tract, nasal cavity or oral cavity, treating and/or preventing obesity and related diseases, or treating and/or preventing food allergies in subjects in need of such treatment. Briefly stated, the current invention provides a process for producing milk fractions rich in secretory Immunoglobulin A, using one or more microporous membrane filtration steps. A preferred protocol of the present process involves de-fatting, micro-filtration and ultrafiltration-concentration through a number of diafiltration cycles.

Abstract: Method for removal of endotoxin from protein preparations using core-shell nanoparticles, which have the ability to selectively adsorb endotoxin molecules in a protein mixture. The method comprises the steps of (a) preparing a plurality of core-shell nanoparticles; (b) adding the core-shell nanoparticles into a protein preparation containing endotoxin; (c) incubating the core-shell nanoparticles with the protein preparation for a period of time; and (d) separating nanoparticles from the protein preparation.

Abstract: The present invention is concerned with the development of a vaccine against Aeromonas hydrophila for use especially in fish. The invention provides an immunogenic S-layer protein of approximately 50 kDa of A. hydrophila for use in the development of a vaccine, as well as the nucleic acid encoding said protein and vaccines comprising said protein or nucleic acid encoding said protein.

Abstract: The invention provides a universal linker capable of synthesizing nucleic acid having a phosphate group at the 3? terminal, a universal support carrying the linker, and a synthesis method of nucleic acid using the universal support. The linker for solid phase synthesis of nucleic acid contains a compound represented by at least one of the following formulae wherein each symbol is as defined in the specification.

Abstract: A method of localizing reproduction assisting hyaluronic acid to reproductive cell surfaces by covalently linking it to lipids is disclosed.

Abstract: A vanadium phthalocyanine compound with low absorptivity in the visible light region and high absorptivity in the near-infrared light region, and represented by the following Formula:

Abstract: Compounds with aryl ring(s) at porphyrin meso position(s) bearing an amino group in position 4 relative to the porphyrin macrocycle, and at least one unsubstituted 5 (hydrogen-bearing) meso position with the 10-, 15-, and/or 20-relationship to the aryl ring bearing the amino group, and metal complexes thereof, feature broad spectral absorption throughout the visible region. These compounds are electropolymerized to form electrically conducting porphyrin and porphyrin-fullerene polymers that are useful in photovoltaic applications. The structure of one such electrically conducting porphyrin polymer is shown below.

Abstract: A method for converting an amorphous drug, such as everolimus, or other macrolide immunosuppressive drug, into a crystalline form. The method utilizes a slurry of the drug in organic liquid phase and ages the slurry to achieve the conversion.

Abstract: Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is a thiazolyl, picolinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: Processes are provided which create an aldehyde methylene, or hydrated or hemiacetal methylene attached to a heteroatom of a 6 membered ring without going through an olefinic group and without the necessity of using an osmium reagent. In particular, a compound of formula (I) can be produced from (II) and avoid the use of an allyl amine: (formulae I and II) where R, P1 P3, R3 and Rx are as described herein.

Abstract: The present invention provides oxazine compounds, method of using and method of making oxazine compounds and its pharmaceutical use.

Abstract: A platinum (II) complex of general formula (II), in which Ar1 is a 1,2-diazole ring, Ar2 is a pyridine ring, and Ar3 is a phenyl ring. Ar1, Ar2, and Ar3 together form a tridentate ligand coordinated to the platinum through atoms X, Y, and Z, respectively, and X, Y, and Z are independently carbon or nitrogen. V represents O, S, N, C, P, or Si, and W is an anion. In some cases, Ar3 is an anion and Ar1 and Ar2 are neutral; in other cases, Ar1 and Ar3 are neutral and Ar2 is an anion. The complexes emit in the UV to near IR range and are useful as emitters for organic light emitting devices.

Abstract: The invention provides novel derivatives of cyclopamine having the following formula:

Abstract: An improved process for the N-alkylation of tertiary morphinan alkaloid bases to form the corresponding quaternary morphinan alkaloid derivatives.

Abstract: To provide a method whereby a 2-azaadamantane can easily be obtained in good yield. A method for producing a 2-azaadamantane represented by the formula (1), which comprises cyclizing a compound represented by the following formula (2) in the presence of an acid.

Abstract: The disclosure generally relates to a process for the preparation of compounds of formula I, including synthetic intermediates which are useful in the process.

Abstract: Methods and processes for preparation and production of deuterated ?-diphenylurea are disclosed. Especially, a kind of deuterated ?-diphenylurea compounds which can inhibit phosphokinase and the preparation method of N-(4-chloro-3-(trifluoromethyl)phenyl)-N?-(4-(2-(N-d3-methylcarbamoyl)-4-pridinyloxy)phenyl)urea are disclosed. The said deuterated diphenylurea compounds can be used for treating or preventing tumors and relative diseases.

Abstract: The present invention relates to compounds of the formula I, wherein A, D, E, L, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

Abstract: An improved process for selectively chlorinating 4,5-dihydro-1-phenyl-1H-1,2,4-triazole-5-ones, including 4,5-dihydro-3-alkyl-1-phenyl-1H-1,2,4-triazole-5-ones and4-haloalkyl-4, 5-dihydro-3-alkyl-1-phenyl-1H-1,2,4-triazole-5-ones in the 4-position of the phenyl ring by dissolving the compounds in a synergistic ratio of polar aprotic solvents, preferably acetonitrile and N,N-dimethylformamide in a 7:3 ratio and reacting the solution with chlorine gas.

Abstract: The present invention relates to a new process for preparing dithiine-tetracarboxy-diimides.

Abstract: To provide a method for producing a wide variety of carbazole derivatives which have a simple and uncomplicated process and in which variations in the yield, purity, etc. of a desired substance which are caused by an aryl group introduced is reduced as much as possible. A method for producing a carbazole derivative represented by General Formula (1) is provided, in which 9-[4-(10-phenyl-9-anthryl)phenyl]-9H-carbazole having an active site at the 3-position of the carbazole skeleton and an aromatic compound having an active site are coupled. In the formula, Ar1 represents an aryl group with 6 to 13 carbon atoms in a ring, and Ar1 may have a substituent.

Abstract: The invention provides a novel class of cyanine dyes that are functionalized with a linker moiety that facilitates their conjugation to other species and substituent groups which increase the water-solubility, and optimize the optical properties of the dyes. Also provided are conjugates of the dyes, methods of using the dyes and their conjugates and kits including the dyes and their conjugates.

Abstract: PROBLEM To provide an environmentally-friendly method for producing industrially an ester compound. SOLUTION The present invention is a method for producing an ester compound which comprises subjecting a carboxylic acid and an alcohol to dehydration-condensation reaction using an involatile acid catalyst and then removing the residual acid catalyst by bringing a weak basic substance into contact with the residual acid catalyst.

Abstract: The present invention concerns groups of compounds derived from tunicates of the Synoicum species, as well as to pharmaceutical compositions comprising these compounds, and uses thereof. Extracts from tunicates show selective toxicity against several different cancer cell lines in the NCI 60 cell line panel. These compounds are useful in the effective treatment of cancers, particularly malignant melanomas, colon cancer, and renal cancer cell lines.

Abstract: What is disclosed in the invention is a preparation method of a supercritical Cinnamomum subavenium extract, which is made from the material, the dried stem of C. subavenium. The extract is obtained by extracting C. subavenium which is pulverized as particles with supercritical carbon dioxide fluid. The C. subavenium extract or its active ingredient, subamolide A, can be used to inhibit the growth of human urothelial carcinoma cell lines. In addition, the C. subavenium extract (or subamolide A) is able to synergistically inhibit the growth of human urothelial carcinoma cell lines with cisplatin (CDDP) or gemcitabine (Gem). Therefore, the C. subavenium extract (or subamolide A) can be an anticancer drug alone, or forms a pharmaceutical composition with CDDP (or Gem) to treat with cancers in respect of urinary system.

Abstract: The present invention relates to a process for the total synthesis of epicocconone analogs of formula (I): The invention also relates to novel epicocconone analogs.

Abstract: The invention relates to recombinant cells and their use in the production of 3,4-dihydroxybutyrate, 2,3-dihydroxybutyrate and 3-hydroxybutyrolactone.

Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).

Abstract: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

Abstract: In the presence invention, a (2R)-2-fluoro-2-C-methyl-D-ribono-?-lactone precursor is produced in the form of a ring-opened fluorinated compound by reaction of a 1,2-diol with sulfuryl fluoride (SO2F2) in the presence of an organic base and, optionally, a fluoride ion source. The production method of the present invention secures less number of process steps as compared to the conventional production method (shortening of three steps: cyclic sulfurous esterification, oxidation and ring-opening fluorination to one step) and satisfies the requirements for industrial production (high yield and high reproductivity). The thus-obtained (2R)-2-fluoro-2-C-methyl-D-ribono-?-lactone precursor is useful as an important intermediate for the synthesis of 2?-deoxy-2?-fluoro-2?-C-methylcytidine with antivirus activity.

Abstract: Described herein are single step methods of making various classes of alkylamine derivatives of furan and tetrahydrofuran by simultaneous contact of a sugar with H2, an acid catalyst and hydrogenation catalyst in the presence of an alkylamide solvent. The hydrogenation catalyst is a heterogeneous catalyst comprising a metal selected from the group consisting of Pt, Pd, and nickel. The acid catalysts may be homogeneous mineral acid or a heterogeneous acid catalyst on substrate. In a preferred practice the two catalysts are provided on a common heterogeneous bifunctional support. Using similar combinations of acid and hydrogenation catalysts, there is also described single step methods for making furandimethanol by simultaneously contacting a hexose with the two separate catalysts in the presence of H2 in an aprotic solvent, such as dimethylformamide.

Abstract: A process for preparing a divinylarene dioxide including (a) reacting at least one divinylarene with hypochlorous acid to form a chlorohydrin; and (b) treating the chlorohydrin formed in step (a) with at least one base, under conditions to form a divinylarene dioxide product.

Abstract: Provided are processes for the oxidative cleavage of a double bond in an unsaturated carboxylic acid. The process includes contacting the unsaturated carboxylic acid with a mild oxidizing agent and agitating the unsaturated carboxylic acid and the mild oxidizing agent for a time sufficient to cleave a double bond of the unsaturated carboxylic acid and produce a product comprising an aldehyde. The process is typically carried out in a mill, such as a ball, hammer, attrition, or jet mill.

Abstract: This invention relates to an organic tungsten complex prepared by providing a strongly acidic tungsten precursor having pH?2.5, and either reacting the tungsten precursor with a nitrogenous base to form a tungsten salt intermediate having a pH ranging from ?5 to ?8.5, and further reacting the tungsten salt intermediate with a fatty acid derivative of an alcohol, wherein the fatty acid derivative of an alcohol contains at least one free hydroxyl group; or reacting the tungsten precursor with a fatty acid derivative of an alcohol, wherein the fatty acid derivative of an alcohol contains at least one free hydroxyl group and a nitrogenous base. Further, this invention relates to lubricating compositions containing the inventive tungsten complexes.

Abstract: There is described a process for preparing silylamines in and particularly trisilylamine (TSA) in high yields in a tubular laminar flow, plug flow reactor, from ammonia gas and a monohalosilane gas. The apparatus can be a tubular flow reactor comprising a first portion of the reactor defining a gas entry zone, a second portion of the reactor defining a reaction zone and a third portion of the reactor defining a separation zone, the reaction zone providing a reactant contacting region. Trisilylamine can be recovered in the separation zone in a cold trap collection vessel.

Abstract: Amino group-containing organosilicon compounds containing no or only a small fraction of Si-bonded hydroxyl groups are prepared by preparing an organosilicon compound containing amino groups and Si-bonded hydroxyl groups by equilibration in the presence of an equilibration catalyst, and reacting the resultant product with a cyclic silazane. The products are particularly useful as a monomer or macromere for the preparation of high molecular weight organic polymers containing organosilicon blocks.